CDK9 and cancer: In [66], the cytotoxic effect of a dual-functional inhibitor acting on both class I HDAC (HDAC1 and HDAC3) and cyclin-dependent kinase 9 (CDK9), which is an important activator of transcriptional regulation, was investigated in relation to MDA-MB-231 cancer cells.